SCHEMBL12336352

SCHEMBL12336352

CNC1CCN(CC(=O)O)CC1

nearest known ligand 0.54

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.44
CARM1 Q86X55 1/20 0.39
PRMT6 Q96LA8 1/20 0.39
PDE4B Q07343 1/20 0.37
ITGB3 P05106 1/20 0.36
ITGA2B P08514 1/20 0.36
HTT P42858 1/20 0.36
ALDH1A1 P00352 1/20 0.36
PKM P14618 1/20 0.36
SFRP1 Q8N474 1/20 0.36
SCN9A Q15858 1/20 0.36
KMT2A Q03164 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
S1PR1 P21453 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29391873 0.86 ALDH1A1 (0.37) CARM1PRMT6HTTALDH1A1PKM
SCHEMBL11927511 0.84 ALDH1A1 (0.36) CARM1PRMT6ALDH1A1PKMKMT2A
SCHEMBL10316243 0.82 PKM (0.49) CARM1PRMT6HTTALDH1A1PKM
SCHEMBL17207600 0.82 CYP11B2 (0.41) HTTALDH1A1KMT2A
SCHEMBL13798599 0.81 HSD17B10 (0.41) HSD17B10PDE4BITGB3ITGA2BHTT
SCHEMBL8337260 0.81 SMN1; SMN2 (0.42) ALDH1A1KMT2ASMN1; SMN2
SCHEMBL669964 0.81 LTA4H (0.45) HSD17B10CARM1PRMT6ALDH1A1PKM
SCHEMBL12404059 0.79 KMT2A (0.42) HSD17B10PDE4BITGB3ITGA2BHTT
SCHEMBL14887154 0.79 ALDH1A1 (0.46) CARM1PRMT6ALDH1A1PKMKMT2A
SCHEMBL13282353 0.79 KMT2A (0.36) CARM1PRMT6ALDH1A1PKMKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170260174-A1 Benzene, Pyridine, and Pyridazine Derivatives ESANEX INC (US) 2017-09-14 US disclosed
EP-2380879-B1 Tetrahydroindolone and tetrahydroindazolone derivatives ESANEX INC (US) 2017-07-12 EP disclosed
US-9656956-B2 Benzene, pyridine, and pyridazine derivatives ESANEX, INC. (US) 2017-05-23 US disclosed
CN-103582638-B Heteroaryl pyrimidine derivative, preparation method and application thereof JIANGSU HANSOH PHARMACEUTICAL Co.,Ltd. (CN) 2016-02-10 CN disclosed
US-20140343037-A1 BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES SERENEX, INC. 2014-11-20 US disclosed
US-20130137686-A1 BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES SERENEX, INC. 2013-05-30 US disclosed
CN-102911172-A Heteroaryl pyrimidine derivatives and preparation method and application thereof SHANGHAI HENGRUI MEDICINE CO LTD 2013-02-06 CN disclosed
US-8309548-B2 Benzene, pyridine, and pyridazine derivatives SERENEX, INC. (US) 2012-11-13 US disclosed
WO-2011113578-A1 NEW OXADIAZOLE DERIVATIVES ALMIRALL, S.A. (ES) 2011-09-22 WO disclosed
US-20110183977-A1 BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES SERENEX, INC. (US) 2011-07-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130137686-A1 BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES CDK4, P2RX4, MKI67 HSD17B10 3780/4885CARM1 3353/4885PRMT6 2269/4885
US-20170260174-A1 Benzene, Pyridine, and Pyridazine Derivatives CDK4, P2RX4, MKI67 HSD17B10 3780/4885CARM1 3353/4885PRMT6 2269/4885
US-20140343037-A1 BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES CDK4, P2RX4, MKI67 HSD17B10 3780/4885CARM1 3353/4885PRMT6 2269/4885
US-20110183977-A1 BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES CDK4, P2RX4, MKI67 HSD17B10 3780/4885CARM1 3353/4885PRMT6 2269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.